{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338000","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2026-08-06T20:10:06+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:13:41.858539+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tectonic Q2 net loss $22.3M; cash $227M; TX45 Phase 2 enrollment complete, IDMC recommends continuation","bullets":["Net loss of $22.3M for Q2 2026 vs $20.0M in Q2 2025; R&D expenses $18.0M, G&A $6.2M.","Cash and cash equivalents $227.1M as of June 30, 2026; cash runway into Q1 2029.","TX45 APEX Phase 2 trial in PH-HFpEF completed enrollment (191 patients, 137 with CpcPH); IDMC recommended continuation; topline results expected early Q1 2027.","TX2100 Phase 1a single dose cohorts completed; topline results expected by end of Q3 2026; Phase 2 planned early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338000","json":"https://secwatch.observer/filing/0001193125-26-338000.json","markdown":"https://secwatch.observer/filing/0001193125-26-338000.md","text":"https://secwatch.observer/filing/0001193125-26-338000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/0001193125-26-338000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:13:41.858539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}